Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brolucizumab vs Aflibercept in nAMD (TALON)
NCT04005352Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2019
- Primary completion
- Sep 2022
- Modality
- scFv Fragments, Monoclonal Antibodies
- Countries
- 20
01
Overview
A Phase 3 trial of brolucizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Novartis. Started Sep 2019; status: completed.
02
Drugs
brolucizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04005352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04005352.